1Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY, USA 2Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA 3Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, USA 4Physiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA 5Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA 6Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, USA
OPEN PEER REVIEW
REVIEWER STATUS
Abstract
Tertiary lymphoid organs are found at sites of chronic inflammation in autoimmune diseases such as systemic lupus erythematosus and rheumatoid arthritis. These organized accumulations of T and B cells resemble secondary lymphoid organs and generate autoreactive effector cells. However, whether they contribute to disease pathogenesis or have protective functions is unclear. Here, we discuss how tertiary lymphoid organs can generate potentially pathogenic cells but may also limit the extent of the response and damage in autoimmune disease.
Corresponding author:
Theresa T. Lu
Competing interests:
The authors declare that they have no competing interests.
Grant information:
This work was supported by MSTP T32GM007739 from NIGMS/NIH to the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program (WDS), Lupus Research Alliance (TTL), St. Giles Foundation (TTL), and an O’Neill Foundation grant from the Barbara Volcker Center for Women and Rheumatic Diseases (TTL).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis are marked by chronic inflammation in end organs that can be associated with the development of tertiary lymphoid organs (TLOs)1–6. TLOs are also known as tertiary lymphoid tissues, ectopic lymphoid follicles, or ectopic lymphoid structures and are accumulations of lymphocytes and stromal cells in an organized structure that occur outside of secondary lymphoid organs (SLOs). TLOs share many features with SLOs, such as the presence of T and B cell compartmentalization into T cell zones and B cell follicles, chemokines that mediate the compartmentalization, antigen-presenting cells, lymphatic sinuses, high endothelial venules, follicular dendritic cells, and fibroblastic reticular cells (FRCs)7–11. In SLE, inflammation in the kidney interstitial tissue is associated with greater risk for kidney failure12. Up to almost half of patients have well-circumscribed aggregates of B cells, plasma cells, and T cells and a small fraction can have well-organized germinal centers with follicular dendritic cells1,2. In rheumatoid arthritis, TLOs ranging from B and T cell aggregates to germinal centers are found in the inflamed synovium of about half of biopsied patients and are associated with more severe joint and systemic inflammation3–6,13. TLOs are also found in other organs in other autoimmune diseases or models, such as in the salivary and lacrimal glands in Sjögren’s syndrome14–16, the central nervous system in multiple sclerosis7,17–22, the pancreas in diabetes23–25, the thymus in myasthenia gravis26,27, and the intestines in inflammatory bowel disease28,29. While findings in recent years have begun to delineate the mechanisms that regulate the formation of TLOs (recently reviewed in 7–11), it is unclear whether TLOs provide pathogenic or protective contributions to SLE, rheumatoid arthritis, and other autoimmune diseases. Here we will review evidence that TLOs may generate potentially pathogenic cells but that they may limit the extent of pathogenic cell activity.
Tertiary lymphoid organs can generate potentially pathogenic cells
In the setting of infections, TLOs have been generally considered to be protective, adopting SLO-like functions and acting as “outposts” of SLOs that are directly positioned at the site of inflammation. TLOs form in the lung of influenza-infected mice30–32 that can maintain and reactivate memory CD8+ T cells33 and produce plasma cells and antiviral serum immunoglobulins31. Remarkably, although there is a delay in anti-viral immunity development, TLOs are sufficient for protection when the hosts are deficient in SLOs33, underscoring the idea that TLOs can generate effector cells that provide effective host defense. Innate lymphoid cells (ILCs) in the lung are induced after influenza infection and have been shown to maintain lung function, epithelial integrity, and airway remodeling34. Although it is unknown whether TLOs play a role in maintaining or stimulating lung ILCs after influenza infection, ILCs have been shown to be associated with TLOs and have even been associated with decreased disease progression in lung cancer35–37. It is possible that influenza-induced lung TLOs also provide a suitable environment for ILCs to populate and function in a protective manner. Similar to influenza virus infection, TLOs form with pulmonary Mycobacterium tuberculosis (MTB) infection38–40. Latent tuberculosis is associated with more frequent, well-organized TLOs while TLOs are less frequent and less well-formed in active tuberculosis40, suggesting a protective role for TLOs in controlling disease. The TLOs contribute to the formation of granulomas, which function to promote immunity and limit tissue damage41. Additionally, CXCL13 expression that organizes the B cell follicles serves to recruit CXCR5-expressing T helper (Th) cells into granulomas to activate macrophages that are essential to infection control38,40. These studies on TLOs in infection models highlight the ability of TLOs to support immune responses that are capable of protecting the host.
Similar to immune responses generated in SLOs, immune responses targeted to self may be harmful to the host. The TLOs in SLE kidneys contain germinal centers that show clonal expansion and somatic hypermutation characteristic of germinal center responses in SLOs2, demonstrating well-developed effector responses. The TLOs correlate strongly with the presence of immune complexes, suggesting that the locally generated antibodies are autoantibodies to renal antigens that can fix complement and thus cause tissue inflammation and damage2. Similarly, the B cell responses associated with TLOs in the rheumatoid arthritis synovium42, the salivary glands in Sjögren’s syndrome43, and other target tissues show autoimmunity10. SLE kidneys and rheumatoid synovium are also characterized by the accumulation of Th17 cells, which can have proinflammatory roles44–48. While IL-17-expressing cells could help to induce TLO formation, as has been shown in the central nervous system and in neonatal lung20,22,49, the TLOs could potentially also help to support Th17 cell maintenance or acquisition of additional proinflammatory properties20,50,51. Indeed, B cells are necessary for the accumulation of activated T cells, likely by presenting antigen to the T cells52–54, and B cells in TLOs may be pathogenic in part by stimulating autoreactive T cells, which then can contribute to the inflammatory milieu in the affected end organs. TLOs in autoimmune diseases, then, can be a source of potentially pathogenic lymphocytes.
Tertiary lymphoid organs can potentially limit pathogenic responses
Despite the generation of autoreactive and proinflammatory cells, TLOs could also have a protective role by sequestering pathogenic lymphocytes and preventing them from leaving the specific tissue or tissue compartment to cause further damage. For example, in SLE, glomerular damage is unrelated to the extent of interstitial inflammation12, but failure to sequester lymphocytes within the interstitial tissue could potentially result in the migration of lymphocytes to the glomeruli and worsened glomerular damage. Alternatively, in the absence of TLOs, the lymphocytes could enter the circulation to home to and potentially damage additional organs outside the kidneys. That inflammatory cells are able to find alternative niches despite the absence of TLOs is seen in MTB infection, where antigen-specific T cells still accumulate, showing an altered, perivascular location, in the absence of TLOs38,40. Also, B cell selection in the pancreas is unaltered by follicular disruption of TLO in the pancreas of non-obese diabetic mice25. Interestingly, TLOs within tumors but not at the tumor periphery are correlated with good outcomes in a study of pancreatic carcinoma patients55, raising the possibility that the TLOs at the tumor periphery prevent potential anti-tumor lymphocytes from accessing the tumor parenchyma. The concept that TLOs might have a sequestration function is analogous to the sequestration of lymphocytes within SLOs with the S1P agonist fingolimod, which is used to treat multiple sclerosis56. Fingolimod downregulates SIP receptor 1, preventing lymphocyte egress from the SLOs and subsequent migration to end organs57. Sequestration of potentially pathogenic cells, then, may help limit the extent of disease.
TLOs can also be protective if they provide a microenvironment that generates regulatory or reparative cells that reduce the pathogenicity of inflammatory cells. In the apoE-/- model of atherosclerosis, TLOs that form on the outer aspects of the atherosclerotic vessel wall generate regulatory T cells (Tregs). These TLOs are dependent on lymphotoxin β receptor (LTβR) stimulation of presumably local vascular smooth muscle, and preventing TLO formation by deleting LTβR from smooth muscle cells resulted in more and enlarged plaques58. These results suggested that the TLOs were protective, perhaps by the generation of the Tregs. Here, the TLO stroma may be critical for the generation of regulatory cells. Lymph node FRCs have been implicated in Treg generation by presenting self-antigen on MHCII and by guiding T cells into a tolerance-inducing environment59,60. FRCs, along with endothelial cells, can additionally promote tolerance by MHCI presentation of autoantigen61,62 and regulate the magnitude of T cell activation by expressing inducible nitric oxide synthase63–65. Tregs have also been shown to mediate tissue repair via amphiregulin in lung with influenza infection66 and in muscle after injury67, and thus TLO generation of Tregs can have protective effects independent of their immunosuppressive functions. Similarly, ILCs are another source of amphiregulin that is important for repair34, and TLOs may potentially support their development68. Interestingly, both SLE patients and lupus-prone mice possess decreased numbers and abnormal function of Tregs69–72 while exhibiting increased calcium/calmodulin-dependent protein kinase IV (CamK4)73,74, which is responsible for an imbalance in Th17 cells and Tregs with a shift towards more Th17 cells. Inhibition of CamK4 corrected this imbalance in lupus-prone mice, decreasing Th17 cells and increasing Tregs in the kidney in association with reduced organ damage75. It is tempting to speculate that the TLOs (and perhaps the SLOs) in SLE do not function correctly to foster optimal Treg generation. TLOs, then, may not only sequester potentially pathogenic cells but also provide an environment that limits the magnitude or severity of the response.
Conclusion
In conclusion, in autoimmune diseases, TLOs can generate and harbor autoreactive and proinflammatory, potentially pathogenic lymphocytes but could potentially serve to limit pathogenic responses by sequestering these cells or by reducing the magnitude of the response. Therapeutically, targeting TLOs may offer opportunities to ameliorate disease, and more understanding of the potential pathogenic and protective functions is needed. For example, can we identify TLOs that generate more pathogenic cells versus those that have more regulatory functions? Do these different functions in part reflect the evolution of TLO development and maturation? What are the vascular, stromal, and hematopoietic elements that contribute to the different microenvironments, and can we modulate them to generate a more immunoregulatory environment? Furthermore, understanding how the affected tissue outside the TLOs may be similar or distinct in supporting the generation and maintenance of autoreactive lymphocytes would enrich our understanding of the distinct nature of TLOs and also allow us to prevent the lymphocytes from potentially accumulating elsewhere upon TLO disruption. Continued improved understanding of TLO biology will help us better understand how to treat autoimmune disease.
Author contributions
All authors contributed to the writing of this manuscript.
Competing interests
The authors declare that they have no competing interests.
Grant information
This work was supported by MSTP T32GM007739 from NIGMS/NIH to the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program (WDS), Lupus Research Alliance (TTL), St. Giles Foundation (TTL), and an O’Neill Foundation grant from the Barbara Volcker Center for Women and Rheumatic Diseases (TTL).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
F1000 recommended
References
1.
Steinmetz OM, Velden J, Kneissler U, et al.:
Analysis and classification of B-cell infiltrates in lupus and ANCA-associated nephritis.
Kidney Int.
2008; 74(4): 448–57. PubMed Abstract
| Publisher Full Text
| F1000 Recommendation
3.
Humby F, Bombardieri M, Manzo A, et al.:
Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium.
PLoS Med.
2009; 6(1): e1. PubMed Abstract
| Publisher Full Text
| Free Full Text
4.
Wengner AM, Höpken UE, Petrow PK, et al.:
CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis.
Arthritis Rheum.
2007; 56(10): 3271–83. PubMed Abstract
| Publisher Full Text
5.
Shi K, Hayashida K, Kaneko M, et al.:
Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients.
J Immunol.
2001; 166(1): 650–5. PubMed Abstract
| Publisher Full Text
12.
Hsieh C, Chang A, Brandt D, et al.:
Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring.
Arthritis Care Res (Hoboken).
2011; 63(6): 865–74. PubMed Abstract
| Publisher Full Text
| Free Full Text
13.
Thurlings RM, Wijbrandts CA, Mebius RE, et al.:
Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype.
Arthritis Rheum.
2008; 58(6): 1582–9. PubMed Abstract
| Publisher Full Text
14.
Fava RA, Kennedy SM, Wood SG, et al.:
Lymphotoxin-beta receptor blockade reduces CXCL13 in lacrimal glands and improves corneal integrity in the NOD model of Sjögren's syndrome.
Arthritis Res Ther.
2011; 13(6): R182. PubMed Abstract
| Publisher Full Text
| Free Full Text
15.
Bombardieri M, Barone F, Lucchesi D, et al.:
Inducible tertiary lymphoid structures, autoimmunity, and exocrine dysfunction in a novel model of salivary gland inflammation in C57BL/6 mice.
J Immunol.
2012; 189(7): 3767–76. PubMed Abstract
| Publisher Full Text
| Free Full Text
16.
Holdgate N, St Clair EW:
Recent advances in primary Sjogren's syndrome [version 1; referees: 3 approved].
F1000Res.
2016; 5: pii: F1000 Faculty Rev-1412. PubMed Abstract
| Publisher Full Text
| Free Full Text
17.
Columba-Cabezas S, Griguoli M, Rosicarelli B, et al.:
Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein.
J Neuroimmunol.
2006; 179(1–2): 76–86. PubMed Abstract
| Publisher Full Text
18.
Magliozzi R, Columba-Cabezas S, Serafini B, et al.:
Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis.
J Neuroimmunol.
2004; 148(1–2): 11–23. PubMed Abstract
| Publisher Full Text
20.
Peters A, Pitcher LA, Sullivan JM, et al.:
Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation.
Immunity.
2011; 35(6): 986–96. PubMed Abstract
| Publisher Full Text
| Free Full Text
21.
Serafini B, Rosicarelli B, Magliozzi R, et al.:
Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis.
Brain Pathol.
2004; 14(2): 164–74. PubMed Abstract
| Publisher Full Text
22.
Pikor NB, Astarita JL, Summers-Deluca L, et al.:
Integration of Th17- and Lymphotoxin-Derived Signals Initiates Meningeal-Resident Stromal Cell Remodeling to Propagate Neuroinflammation.
Immunity.
2015; 43(6): 1160–73. PubMed Abstract
| Publisher Full Text
| F1000 Recommendation
23.
Astorri E, Bombardieri M, Gabba S, et al.:
Evolution of ectopic lymphoid neogenesis and in situ autoantibody production in autoimmune nonobese diabetic mice: cellular and molecular characterization of tertiary lymphoid structures in pancreatic islets.
J Immunol.
2010; 185(6): 3359–68. PubMed Abstract
| Publisher Full Text
24.
Ludewig B, Odermatt B, Landmann S, et al.:
Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue.
J Exp Med.
1998; 188(8): 1493–501. PubMed Abstract
| Publisher Full Text
| Free Full Text
25.
Henry RA, Kendall PL:
CXCL13 blockade disrupts B lymphocyte organization in tertiary lymphoid structures without altering B cell receptor bias or preventing diabetes in nonobese diabetic mice.
J Immunol.
2010; 185(3): 1460–5. PubMed Abstract
| Publisher Full Text
| Free Full Text
26.
Hill ME, Shiono H, Newsom-Davis J, et al.:
The myasthenia gravis thymus: a rare source of human autoantibody-secreting plasma cells for testing potential therapeutics.
J Neuroimmunol.
2008; 201–202: 50–6. PubMed Abstract
| Publisher Full Text
27.
Zhang X, Liu S, Chang T, et al.:
Intrathymic Tfh/B Cells Interaction Leads to Ectopic GCs Formation and Anti-AChR Antibody Production: Central Role in Triggering MG Occurrence.
Mol Neurobiol.
2016; 53(1): 120–31. PubMed Abstract
| Publisher Full Text
29.
Olivier BJ, Cailotto C, van der Vliet J, et al.:
Vagal innervation is required for the formation of tertiary lymphoid tissue in colitis.
Eur J Immunol.
2016; 46(10): 2467–80. PubMed Abstract
| Publisher Full Text
| F1000 Recommendation
30.
Moyron-Quiroz JE, Rangel-Moreno J, Kusser K, et al.:
Role of inducible bronchus associated lymphoid tissue (iBALT) in respiratory immunity.
Nat Med.
2004; 10(9): 927–34. PubMed Abstract
| Publisher Full Text
| F1000 Recommendation
31.
GeurtsvanKessel CH, Willart MA, Bergen IM, et al.:
Dendritic cells are crucial for maintenance of tertiary lymphoid structures in the lung of influenza virus-infected mice.
J Exp Med.
2009; 206(11): 2339–49. PubMed Abstract
| Publisher Full Text
| Free Full Text
| F1000 Recommendation
32.
Halle S, Dujardin HC, Bakocevic N, et al.:
Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.
J Exp Med.
2009; 206(12): 2593–601. PubMed Abstract
| Publisher Full Text
| Free Full Text
33.
Moyron-Quiroz JE, Rangel-Moreno J, Hartson L, et al.:
Persistence and responsiveness of immunologic memory in the absence of secondary lymphoid organs.
Immunity.
2006; 25(4): 643–54. PubMed Abstract
| Publisher Full Text
34.
Monticelli LA, Sonnenberg GF, Abt MC, et al.:
Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus.
Nat Immunol.
2011; 12(11): 1045–54. PubMed Abstract
| Free Full Text
| F1000 Recommendation
35.
Carrega P, Loiacono F, Di Carlo E, et al.:
NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures.
Nat Commun.
2015; 6: 8280. PubMed Abstract
| Publisher Full Text
| F1000 Recommendation
36.
Meier D, Bornmann C, Chappaz S, et al.:
Ectopic lymphoid-organ development occurs through interleukin 7-mediated enhanced survival of lymphoid-tissue-inducer cells.
Immunity.
2007; 26(5): 643–54. PubMed Abstract
| Publisher Full Text
37.
Schmutz S, Bosco N, Chappaz S, et al.:
Cutting edge: IL-7 regulates the peripheral pool of adult ROR gamma+ lymphoid tissue inducer cells.
J Immunol.
2009; 183(4): 2217–21. PubMed Abstract
| Publisher Full Text
38.
Khader SA, Rangel-Moreno J, Fountain JJ, et al.:
In a murine tuberculosis model, the absence of homeostatic chemokines delays granuloma formation and protective immunity.
J Immunol.
2009; 183(12): 8004–14. PubMed Abstract
| Publisher Full Text
| Free Full Text
39.
Ulrichs T, Kosmiadi GA, Trusov V, et al.:
Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung.
J Pathol.
2004; 204(2): 217–28. PubMed Abstract
| Publisher Full Text
40.
Slight SR, Rangel-Moreno J, Gopal R, et al.:
CXCR5+ T helper cells mediate protective immunity against tuberculosis.
J Clin Invest.
2013; 123(2): 712–26. PubMed Abstract
| Publisher Full Text
| Free Full Text
41.
Bean AG, Roach DR, Briscoe H, et al.:
Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin.
J Immunol.
1999; 162(6): 3504–11. PubMed Abstract
42.
Corsiero E, Bombardieri M, Carlotti E, et al.:
Single cell cloning and recombinant monoclonal antibodies generation from RA synovial B cells reveal frequent targeting of citrullinated histones of NETs.
Ann Rheum Dis.
2016; 75(10): 1866–75. PubMed Abstract
| Publisher Full Text
| Free Full Text
| F1000 Recommendation
43.
Salomonsson S, Jonsson MV, Skarstein K, et al.:
Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren's syndrome.
Arthritis Rheum.
2003; 48(11): 3187–201. PubMed Abstract
| Publisher Full Text
44.
Pisitkun P, Ha HL, Wang H, et al.:
Interleukin-17 cytokines are critical in development of fatal lupus glomerulonephritis.
Immunity.
2012; 37(6): 1104–15. PubMed Abstract
| Publisher Full Text
| Free Full Text
46.
Crispín JC, Oukka M, Bayliss G, et al.:
Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.
J Immunol.
2008; 181(12): 8761–6. PubMed Abstract
| Publisher Full Text
| Free Full Text
47.
Genovese MC, Durez P, Richards HB, et al.:
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
J Rheumatol.
2014; 41(3): 414–21. PubMed Abstract
| Publisher Full Text
| F1000 Recommendation
48.
Hirota K, Yoshitomi H, Hashimoto M, et al.:
Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model.
J Exp Med.
2007; 204(12): 2803–12. PubMed Abstract
| Publisher Full Text
| Free Full Text
| F1000 Recommendation
52.
Chan OT, Madaio MP, Shlomchik MJ:
B cells are required for lupus nephritis in the polygenic, Fas-intact MRL model of systemic autoimmunity.
J Immunol.
1999; 163(7): 3592–6. PubMed Abstract
53.
Chan OT, Hannum LG, Haberman AM, et al.:
A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus.
J Exp Med.
1999; 189(10): 1639–48. PubMed Abstract
| Publisher Full Text
| Free Full Text
54.
Weyand CM, Goronzy JJ, Takemura S, et al.:
Cell-cell interactions in synovitis. Interactions between T cells and B cells in rheumatoid arthritis.
Arthritis Res.
2000; 2(6): 457–63. PubMed Abstract
| Publisher Full Text
| Free Full Text
56.
Brinkmann V, Billich A, Baumruker T, et al.:
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
Nat Rev Drug Discov.
2010; 9(11): 883–97. PubMed Abstract
| Publisher Full Text
57.
Matloubian M, Lo CG, Cinamon G, et al.:
Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1.
Nature.
2004; 427(6972): 355–60. PubMed Abstract
| Publisher Full Text
58.
Hu D, Mohanta SK, Yin C, et al.:
Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin β Receptors.
Immunity.
2015; 42(6): 1100–15. PubMed Abstract
| Publisher Full Text
| Free Full Text
| F1000 Recommendation
63.
Lukacs-Kornek V, Malhotra D, Fletcher AL, et al.:
Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated T cell pool in lymph nodes.
Nat Immunol.
2011; 12(11): 1096–104. PubMed Abstract
| Publisher Full Text
| Free Full Text
64.
Siegert S, Huang HY, Yang CY, et al.:
Fibroblastic reticular cells from lymph nodes attenuate T cell expansion by producing nitric oxide.
PLoS One.
2011; 6(11): e27618. PubMed Abstract
| Publisher Full Text
| Free Full Text
69.
Valencia X, Yarboro C, Illei G, et al.:
Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus.
J Immunol.
2007; 178(4): 2579–88. PubMed Abstract
| Publisher Full Text
71.
Scalapino KJ, Tang Q, Bluestone JA, et al.:
Suppression of disease in New Zealand Black/New Zealand White lupus-prone mice by adoptive transfer of ex vivo expanded regulatory T cells.
J Immunol.
2006; 177(3): 1451–9. PubMed Abstract
| Publisher Full Text
72.
Liu MF, Wang CR, Fung LL, et al.:
Decreased CD4+CD25+ T cells in peripheral blood of patients with systemic lupus erythematosus.
Scand J Immunol.
2004; 59(2): 198–202. PubMed Abstract
| Publisher Full Text
73.
Juang YT, Wang Y, Solomou EE, et al.:
Systemic lupus erythematosus serum IgG increases CREM binding to the IL-2 promoter and suppresses IL-2 production through CaMKIV.
J Clin Invest.
2005; 115(4): 996–1005. PubMed Abstract
| Publisher Full Text
| Free Full Text
74.
Koga T, Ichinose K, Mizui M, et al.:
Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus.
J Immunol.
2012; 189(7): 3490–6. PubMed Abstract
| Publisher Full Text
| Free Full Text
75.
Koga T, Mizui M, Yoshida N, et al.:
KN-93, an inhibitor of calcium/calmodulin-dependent protein kinase IV, promotes generation and function of Foxp3+ regulatory T cells in MRL/lpr mice.
Autoimmunity.
2014; 47(7): 445–50. PubMed Abstract
| Publisher Full Text
| Free Full Text
| F1000 Recommendation
1
Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program, New York, NY, USA 2
Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA 3
Autoimmunity and Inflammation Program, Hospital for Special Surgery, New York, NY, USA 4
Physiology, Biophysics, and Systems Biology Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA 5
Department of Microbiology and Immunology, Weill Cornell Medical College, New York, NY, USA 6
Pediatric Rheumatology, Hospital for Special Surgery, New York, NY, USA
This work was supported by MSTP T32GM007739 from NIGMS/NIH to the Weill Cornell/Rockefeller/Sloan-Kettering Tri-Institutional MD-PhD Program (WDS), Lupus Research Alliance (TTL), St. Giles Foundation (TTL), and an O’Neill Foundation grant from the Barbara Volcker Center for Women and Rheumatic Diseases (TTL).
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Shipman WD, Dasoveanu DC and Lu TT. Tertiary lymphoid organs in systemic autoimmune diseases: pathogenic or protective? [version 1; peer review: 2 approved] F1000Research 2017, 6(F1000 Faculty Rev):196 (https://doi.org/10.12688/f1000research.10595.1)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.
Share
Open Peer Review
Current Reviewer Status:
?
Key to Reviewer Statuses
VIEWHIDE
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
I confirm that I have read this submission and believe that I have an
... Continue reading
Competing Interests: No competing interests were disclosed.
Faculty Reviews are commissioned and written by members of the prestigious Faculty Opinions Faculty, and are edited as a service to our readers. In order to make these reviews as comprehensive and accessible as possible, we seek the reviewers’ input before publication. The reviewers’ names and any additional comments they may have are published alongside the review, as is usual on F1000Research.
I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations -
A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Adjust parameters to alter display
View on desktop for interactive features
Includes Interactive Elements
View on desktop for interactive features
Competing Interests Policy
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Examples of 'Non-Financial Competing Interests'
Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.
You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.
You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).
You work at the same institute as any of the authors.
You hope/expect to benefit (e.g. favour or employment) as a result of your submission.
You are an Editor for the journal in which the article is published.
Examples of 'Financial Competing Interests'
You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.
You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.
You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.
Stay Updated
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Comments on this article Comments (0)